WuXi Biologics (02269) Report Interpretation

Overview

This earnings review assesses WuXi Biologics’ 1H26 results, updated FY26E guidance, forecast revisions and valuation. Nomura views the result as supportive of continued growth and maintains Buy while raising its DCF-based target price.

Core views

WuXi Biologics reported 1H26 revenue of CNY11.8bn, up 18.4% year-on-year and slightly above both Bloomberg consensus and Nomura’s CNY11.5bn estimate. Net profit attributable to shareholders rose 4.3% to CNY2.4bn, ahead of CNY2.2bn consensus and Nomura’s CNY2.0bn forecast. On management’s constant-FX basis, revenue growth was 23.4% year-on-year, indicating that currency movements reduced reported growth. The report attributes revenue growth primarily to pre-IND services, where sales rose 27% year-on-year to CNY5.3bn. Early-stage services increased 9% to CNY1.5bn and late-stage manufacturing rose 11% to CNY4.7bn; management attributed the latter growth profile to timing differences. By geography, North American revenue grew 14% to CNY6.9bn, while China revenue expanded 51% to CNY2.0bn. Excluding WuXi XDC, external sales in the biologics drugs business rose 11% to CNY8.1bn. Profitability improved materially at the operating level. Gross margin rose 3.5 percentage points year-on-year to 46.2%, versus Nomura’s 42% estimate, as economies of scale, higher utilisation and efficiency gains outweighed negative foreign-exchange effects. Operating expenses grew 15.7% to CNY1.6bn, slower than revenue, helping operating profit rise 34% to CNY3.8bn. However, other losses of CNY541mn—mainly foreign-exchange losses and lower investment gains—compared with a CNY361mn gain in 1H25, limiting growth in profit attributable to shareholders despite a tax benefit. Management raised FY26E reported sales-growth guidance to 15-18% year-on-year from 13-17%; on a constant-FX basis, guidance rose to 20-23% from 16-20%. It also guided to FY27E capital expenditure of CNY8.0bn, after FY26E capex of CNY7.1bn, which Nomura interprets as evidence of a rapid expansion pace alongside higher project growth, particularly in May and June. Following the stronger-than-expected first half and the potential for further gains in 2H26F, Nomura raises FY26F revenue and earnings forecasts by 1.8% and 13.7%, respectively. Its revised estimates show FY26F revenue of CNY25.568bn, normalised net profit of CNY5.585bn and fully diluted normalised EPS of CNY1.32; the stock traded at 33.6x FY26F fully diluted EPS. Nomura maintains Buy and raises its target price to HKD60.22 from HKD51.38, using a DCF valuation with an unchanged 10.1% WACC and 4.0% terminal growth rate.

Analysis framework

Nomura compares reported 1H26 revenue, earnings and margins with its own forecasts and market consensus, then examines growth by service line and geography. It links margin performance to utilisation, scale and efficiency, incorporates higher management guidance and expected second-half gains into revised forecasts, and values the shares using a discounted cash flow model.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  Nomura derives its HKD60.22 target price from projected cash flows, discounted using a 10.1% WACC and a 4.0% terminal growth rate.

• Industry AnalysisVolume-price decomposition

  Revenue analysis by service line and geography

  The report explains topline growth through sales changes across pre-IND, early-stage and late-stage services, as well as North American and China revenue.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi Biologics (02269.HK)

  Primary covered company; Nomura maintains Buy after a 1H26 earnings beat and higher FY26E guidance.

  Strengths

  Pre-IND sales growth, margin improvement, strong China revenue growth, and expanding project activity.

  Weaknesses

  Other losses, mainly foreign-exchange losses and lower investment gains, constrained net-profit growth.

  Comparison

  1H26 revenue and profit attributable to shareholders exceeded both Bloomberg consensus and Nomura estimates.

  Risks

  Increasing global competition and geopolitical tensions.

Key data

• 1H26 revenueCNY11.8bnUp 18.4% year-on-year; versus CNY11.5bn Bloomberg consensus and Nomura estimate.
• 1H26 profit attributable to shareholdersCNY2.4bnUp 4.3% year-on-year; versus CNY2.2bn consensus and CNY2.0bn Nomura estimate.
• 1H26 gross margin46.2%Up 3.5 percentage points year-on-year; versus Nomura’s 42% estimate.
• FY26E reported revenue-growth guidance15-18% year-on-yearRaised from 13-17%; constant-FX guidance increased to 20-23% from 16-20%.
• FY26F forecast revisionsRevenue +1.8%; earnings +13.7%Reflects the first-half beat and potential gains in 2H26F.
• FY27E capex guidanceCNY8.0bnCompared with FY26E capex of CNY7.1bn.
• Target priceHKD60.22Raised from HKD51.38; based on 10.1% WACC and 4.0% terminal growth.

Impact & implications

Nomura believes the earnings beat, stronger margin and higher FY26E growth guidance support higher earnings expectations and its increased DCF target price. The report also sees the planned capex trajectory as consistent with continued expansion in client projects.

Risks

• Increasing global competition could impede achievement of the target price.
• Geopolitical tensions could impede achievement of the target price.

What to watch

• Delivery against the raised FY26E reported revenue-growth guidance of 15-18% and constant-FX guidance of 20-23%.
• The pace of project growth and execution of FY26E and FY27E capital expenditure plans.
• Whether margin benefits from utilisation, scale and efficiency continue to offset foreign-exchange effects.
• Growth in pre-IND services, late-stage manufacturing, North America and China.